Q2 EPS Estimates for Pyxis Oncology Lowered by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Stock analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Pyxis Oncology in a research note issued on Friday, May 15th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.38) per share for the quarter, down from their prior estimate of ($0.36). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.23) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($0.99) EPS, Q1 2027 earnings at ($0.19) EPS, Q2 2027 earnings at ($0.19) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.20) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.35) EPS.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02).

Other analysts also recently issued research reports about the stock. Stifel Nicolaus decreased their price target on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, March 24th. Wedbush began coverage on Pyxis Oncology in a research note on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.83.

Pyxis Oncology Stock Down 11.4%

Shares of NASDAQ:PYXS opened at $2.02 on Tuesday. Pyxis Oncology has a 52-week low of $0.97 and a 52-week high of $5.55. The company has a 50 day moving average of $1.73 and a two-hundred day moving average of $2.28. The company has a market capitalization of $126.97 million, a price-to-earnings ratio of -1.54 and a beta of 1.43.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Laurion Capital Management LP grew its holdings in Pyxis Oncology by 32.3% during the fourth quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock worth $5,516,000 after acquiring an additional 1,170,505 shares during the period. Vanguard Group Inc. grew its holdings in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after acquiring an additional 14,566 shares during the period. 683 Capital Management LLC grew its holdings in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock worth $1,026,000 after acquiring an additional 366,910 shares during the period. Renaissance Technologies LLC grew its holdings in Pyxis Oncology by 22.0% during the first quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after acquiring an additional 160,300 shares during the period. Finally, Jane Street Group LLC grew its holdings in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock worth $904,000 after acquiring an additional 482,310 shares during the period. 39.07% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.